A federal judge in New Jersey issued an injunction permanently barring Mylan Pharmaceuticals from selling generic topiramate tablets and capsules in the United States before September 26, 2008, the expiration date of the patent for TOPAMAX (topiramate) held by Ortho-McNeil Neurologics Inc. Mylan had challenged the validity of that patent and filed an abbreviated new drug application to market a generic version of the epilepsy drug. The branded manufacturer countered with a patent infringement complaint against Mylan and obtained a preliminary injunction against the generic firm last fall.
Get to know RESPIMAT, the slow-moving mist inhaler from Boehringer Ingelheim Pharmaceuticals, Inc.
Watch the RESPIMAT video and test your knowledge with a short multiple-choice quiz. When you get all the answers right, you’ll receive a certificate naming you a RESPIMAT T.O.P. Performer. Why not check it out today?
Clinical features with downloadable PDFs